Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

Ann Lii Cheng, Chao A. Hsiung, Ih Jen Su, Pei Jer Chen, Ming Chih Chang, Chao Jung Tsao, Woei Yao Kao, Wu Ching Uen, Chih Hung Hsu, Hwei Fan Tien, Tsu Yi Chao, Li Tzong Chen, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

Reactivation of hepatitis is one of the most serious complications of chemotherapy in lymphoma patients who are carriers of the hepatitis B virus (HBV). Glucocorticoids are linked to increased risk of HBV reactivation. This study seeks to clarify whether removal of glucocorticoids from chemotherapy regimens may decrease the risk of HBV reactivation. Eligible patients were seropositive for hepatitis B surface antigen (HBsAg) and had histologically proven non-Hodgkin's lymphomas for which intensive chemotherapy was indicated. Patients were randomized to receive either ACE (epirubicin, cyclophosphamide, and etoposide) or PACE (prednisolone + ACE). A total of 50 patients were enrolled, 25 each for the ACE and PACE arms. The cumulative incidence of HBV reactivation at 9 months after starting chemotherapy was 38% and 73% for ACE and PACE arm, respectively (P = .03). The degree of clinical hepatitis was significantly more severe in the PACE arm: 11 patients (44%) in the PACE and 3 patients (13%) in the ACE arm had ALT elevation more than 10-fold of normal (P = .025), and 7 patients (28%) in the PACE and 1 patient (4%) in the ACE arm had icteric hepatitis (P = .049). Complete remission of tumors occurred in 11 (46%) patients in the PACE and 8 (35%) patients in the ACE arm (P = .556). The estimated overall survival rate at 46 months was 68% in the PACE arm and 36% in the ACE arm, respectively (P = .18). In conclusion, steroid-free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg-positive lymphoma patients. However, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma.

Original languageEnglish
Pages (from-to)1320-1328
Number of pages9
JournalHepatology
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 1 2003
Externally publishedYes

Fingerprint

Hepatitis B virus
Lymphoma
Prednisolone
Steroids
Drug Therapy
Hepatitis
Hepatitis B Surface Antigens
Glucocorticoids
Epirubicin
Incidence
Etoposide
Non-Hodgkin's Lymphoma
Cyclophosphamide
Survival Rate

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology

Cite this

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. / Cheng, Ann Lii; Hsiung, Chao A.; Su, Ih Jen; Chen, Pei Jer; Chang, Ming Chih; Tsao, Chao Jung; Kao, Woei Yao; Uen, Wu Ching; Hsu, Chih Hung; Tien, Hwei Fan; Chao, Tsu Yi; Chen, Li Tzong; Whang-Peng, Jacqueline.

In: Hepatology, Vol. 37, No. 6, 01.06.2003, p. 1320-1328.

Research output: Contribution to journalArticle

Cheng, AL, Hsiung, CA, Su, IJ, Chen, PJ, Chang, MC, Tsao, CJ, Kao, WY, Uen, WC, Hsu, CH, Tien, HF, Chao, TY, Chen, LT & Whang-Peng, J 2003, 'Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma', Hepatology, vol. 37, no. 6, pp. 1320-1328. https://doi.org/10.1053/jhep.2003.50220
Cheng, Ann Lii ; Hsiung, Chao A. ; Su, Ih Jen ; Chen, Pei Jer ; Chang, Ming Chih ; Tsao, Chao Jung ; Kao, Woei Yao ; Uen, Wu Ching ; Hsu, Chih Hung ; Tien, Hwei Fan ; Chao, Tsu Yi ; Chen, Li Tzong ; Whang-Peng, Jacqueline. / Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. In: Hepatology. 2003 ; Vol. 37, No. 6. pp. 1320-1328.
@article{57ea1806e69140969fe9956b5414dcc5,
title = "Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma",
abstract = "Reactivation of hepatitis is one of the most serious complications of chemotherapy in lymphoma patients who are carriers of the hepatitis B virus (HBV). Glucocorticoids are linked to increased risk of HBV reactivation. This study seeks to clarify whether removal of glucocorticoids from chemotherapy regimens may decrease the risk of HBV reactivation. Eligible patients were seropositive for hepatitis B surface antigen (HBsAg) and had histologically proven non-Hodgkin's lymphomas for which intensive chemotherapy was indicated. Patients were randomized to receive either ACE (epirubicin, cyclophosphamide, and etoposide) or PACE (prednisolone + ACE). A total of 50 patients were enrolled, 25 each for the ACE and PACE arms. The cumulative incidence of HBV reactivation at 9 months after starting chemotherapy was 38{\%} and 73{\%} for ACE and PACE arm, respectively (P = .03). The degree of clinical hepatitis was significantly more severe in the PACE arm: 11 patients (44{\%}) in the PACE and 3 patients (13{\%}) in the ACE arm had ALT elevation more than 10-fold of normal (P = .025), and 7 patients (28{\%}) in the PACE and 1 patient (4{\%}) in the ACE arm had icteric hepatitis (P = .049). Complete remission of tumors occurred in 11 (46{\%}) patients in the PACE and 8 (35{\%}) patients in the ACE arm (P = .556). The estimated overall survival rate at 46 months was 68{\%} in the PACE arm and 36{\%} in the ACE arm, respectively (P = .18). In conclusion, steroid-free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg-positive lymphoma patients. However, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma.",
author = "Cheng, {Ann Lii} and Hsiung, {Chao A.} and Su, {Ih Jen} and Chen, {Pei Jer} and Chang, {Ming Chih} and Tsao, {Chao Jung} and Kao, {Woei Yao} and Uen, {Wu Ching} and Hsu, {Chih Hung} and Tien, {Hwei Fan} and Chao, {Tsu Yi} and Chen, {Li Tzong} and Jacqueline Whang-Peng",
year = "2003",
month = "6",
day = "1",
doi = "10.1053/jhep.2003.50220",
language = "English",
volume = "37",
pages = "1320--1328",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

AU - Cheng, Ann Lii

AU - Hsiung, Chao A.

AU - Su, Ih Jen

AU - Chen, Pei Jer

AU - Chang, Ming Chih

AU - Tsao, Chao Jung

AU - Kao, Woei Yao

AU - Uen, Wu Ching

AU - Hsu, Chih Hung

AU - Tien, Hwei Fan

AU - Chao, Tsu Yi

AU - Chen, Li Tzong

AU - Whang-Peng, Jacqueline

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Reactivation of hepatitis is one of the most serious complications of chemotherapy in lymphoma patients who are carriers of the hepatitis B virus (HBV). Glucocorticoids are linked to increased risk of HBV reactivation. This study seeks to clarify whether removal of glucocorticoids from chemotherapy regimens may decrease the risk of HBV reactivation. Eligible patients were seropositive for hepatitis B surface antigen (HBsAg) and had histologically proven non-Hodgkin's lymphomas for which intensive chemotherapy was indicated. Patients were randomized to receive either ACE (epirubicin, cyclophosphamide, and etoposide) or PACE (prednisolone + ACE). A total of 50 patients were enrolled, 25 each for the ACE and PACE arms. The cumulative incidence of HBV reactivation at 9 months after starting chemotherapy was 38% and 73% for ACE and PACE arm, respectively (P = .03). The degree of clinical hepatitis was significantly more severe in the PACE arm: 11 patients (44%) in the PACE and 3 patients (13%) in the ACE arm had ALT elevation more than 10-fold of normal (P = .025), and 7 patients (28%) in the PACE and 1 patient (4%) in the ACE arm had icteric hepatitis (P = .049). Complete remission of tumors occurred in 11 (46%) patients in the PACE and 8 (35%) patients in the ACE arm (P = .556). The estimated overall survival rate at 46 months was 68% in the PACE arm and 36% in the ACE arm, respectively (P = .18). In conclusion, steroid-free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg-positive lymphoma patients. However, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma.

AB - Reactivation of hepatitis is one of the most serious complications of chemotherapy in lymphoma patients who are carriers of the hepatitis B virus (HBV). Glucocorticoids are linked to increased risk of HBV reactivation. This study seeks to clarify whether removal of glucocorticoids from chemotherapy regimens may decrease the risk of HBV reactivation. Eligible patients were seropositive for hepatitis B surface antigen (HBsAg) and had histologically proven non-Hodgkin's lymphomas for which intensive chemotherapy was indicated. Patients were randomized to receive either ACE (epirubicin, cyclophosphamide, and etoposide) or PACE (prednisolone + ACE). A total of 50 patients were enrolled, 25 each for the ACE and PACE arms. The cumulative incidence of HBV reactivation at 9 months after starting chemotherapy was 38% and 73% for ACE and PACE arm, respectively (P = .03). The degree of clinical hepatitis was significantly more severe in the PACE arm: 11 patients (44%) in the PACE and 3 patients (13%) in the ACE arm had ALT elevation more than 10-fold of normal (P = .025), and 7 patients (28%) in the PACE and 1 patient (4%) in the ACE arm had icteric hepatitis (P = .049). Complete remission of tumors occurred in 11 (46%) patients in the PACE and 8 (35%) patients in the ACE arm (P = .556). The estimated overall survival rate at 46 months was 68% in the PACE arm and 36% in the ACE arm, respectively (P = .18). In conclusion, steroid-free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg-positive lymphoma patients. However, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84984575715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984575715&partnerID=8YFLogxK

U2 - 10.1053/jhep.2003.50220

DO - 10.1053/jhep.2003.50220

M3 - Article

C2 - 12774010

AN - SCOPUS:84984575715

VL - 37

SP - 1320

EP - 1328

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -